Page 4 - Pacific Bioscience News Today

ADVERTISEMENT ADVERTISEMENT Fed. Circ. Probes Alleged Misconduct In DNA Tech IP Fight Law360 (April 6, 2021, 6:41 PM EDT) -- A Federal Circuit judge focused the bulk of his questions Tuesday on allegations that Oxford Nanopore Technologies Ltd. used fearmongering over the COVID-19 pandemic to influence the jury to its advantage in Pacific Biosciences suit over its DNA analysis patents. A three-judge panel was considering Pacific Biosciences of California Inc.s appeal of a Delaware federal jury...

Share this article Share this article ResearchAndMarkets.coms offering. The publisher predicts that the global market for digital genome would witness a CAGR of 9.57% over the forecast period 2021-2028. It garnered $10061.6 million in 2020, and is estimated to generate net revenue of approximately $20902.1 million by 2028. In recent years, the incidence of chronic diseases has amplified, in turn creating a huge burden on the healthcare system. This has majorly created the demand for the adopti...

SoftBank to invest $900m in US gene sequencing firm Pacific Biosciences Genetics is a key element of healthcare puzzles. February 11, 2021 Pacific Biosciences of California Inc said on Wednesday SoftBank Group Corp will invest $900 million in the gene-sequencing firm, sending its shares up 21% before the bell. The latest healthcare investment from SoftBank, in the form of convertible debt, will help accelerate the commercialization of Pacific Biosciences’ gene sequencing technology. Last ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial ... Pacific Biosciences of California, Inc.February 10, 2021 GMT MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Co...

Shares of Pacific Biosciences of California traded to a new 52-week high after the firm reported that a Softbank Group subsidiary will invest $900 million to support its growth initiatives.

These high-flying stocks have been moneymakers since early November.

Is Pacific Biosciences of California (PACB) Stock a Buy For 2021? Baron Discovery Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Discovery Fund returned 25.54% (institutional shares). This was 4.07% lower than the Russell 2000 Growth Index, the Fund’s primary benchmark index. You should check out Baron Discovery Fund’s top 5 stock picks for investors to buy right now, which could be the biggest w...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call Pacific Biosciences of California, Inc.January 27, 2021 GMT MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time. T...

Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue MENLO PARK, Calif., Jan. 11, 2021 — Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full fina...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.